{"nctId":"NCT03237481","briefTitle":"Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)","startDateStruct":{"date":"2017-07-31","type":"ACTUAL"},"conditions":["Postoperative Pain"],"count":418,"armGroups":[{"label":"Treatment Group 1: HTX-011","type":"EXPERIMENTAL","interventionNames":["Drug: HTX-011","Device: Luer-lock applicator","Device: Vial access device"]},{"label":"Treatment Group 2: Bupivacaine HCI","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Bupivacaine HCl"]},{"label":"Treatment Group 3: Saline Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Saline placebo","Device: Luer-lock applicator"]}],"interventions":[{"name":"HTX-011","otherNames":[]},{"name":"Bupivacaine HCl","otherNames":[]},{"name":"Saline placebo","otherNames":[]},{"name":"Luer-lock applicator","otherNames":[]},{"name":"Vial access device","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Is scheduled to undergo a unilateral open inguinal herniorrhaphy with mesh under general anesthesia.\n* Has an American Society of Anesthesiologists Physical Status of I, II, or III.\n* Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or using acceptable contraceptives.\n\nExclusion Criteria:\n\n* Had any prior inguinal hernia repair.\n* Has a planned concurrent surgical procedure.\n* Has other pre existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain.\n* Has a contraindication or a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications.\n* Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months.\n* Has taken NSAIDs within 10 days prior to the scheduled surgery.\n* Has taken opioids within 24 hours prior to the scheduled surgery (3 days for long-acting).\n* Has been administered bupivacaine within 5 days prior to the scheduled surgery.\n* Has initiated treatment with medications within 1 month prior to study drug administration that can impact pain control.\n* Has been administered systemic steroids within 5 half-lives or 10 days prior to administration of study drug.\n* Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.\n* Has a known history of Hepatitis B, human immunodeficiency virus (HIV), or active Hepatitis C.\n* Has uncontrolled anxiety, psychiatric, or neurological disorder that, in the opinion of the Investigator, might interfere with study assessments.\n* Had a malignancy in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.\n* Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse. Note: Subjects with a positive drug screen who are taking an allowed, prescribed medication that is known to result in a positive drug test (eg, amphetamine and dextroamphetamine for attention deficit/hyperactivity disorder) may be eligible for participation in the study. Subjects taking medical marijuana are not allowed to participate in the study.\n* Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half lives.\n* Has undergone 3 or more surgeries within 12 months.\n* Has a body mass index (BMI) \\>39 kg/m2.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 72 Hours Postsurgery (AUC0-72), Compared With Saline Placebo.","description":"Pain intensity is assessed using an 11-point NRS (0-10) where 0 represents \"no pain\" and 10 represents \"worst pain imaginable\" (using windowed worst observation carried forward to adjust for opioid rescue medication use). The theoretical range of AUC0-72 is 0-720. The prescribed activity for NRS-A is sitting up from a resting position.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"269.39","spread":"173.719"},{"groupId":"OG001","value":"350.82","spread":"171.224"}]}]}]},{"type":"SECONDARY","title":"Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 72 Hours Postsurgery (AUC0-72), Compared With Bupivacaine HCl.","description":"Pain intensity is assessed using an 11-point NRS (0-10) where 0 represents \"no pain\" and 10 represents \"worst pain imaginable\" (using windowed worst observation carried forward to adjust for opioid rescue medication use). The theoretical range of AUC0-72 is 0-720. The prescribed activity for NRS-A is sitting up from a resting position.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"269.39","spread":"173.719"},{"groupId":"OG001","value":"341.88","spread":"158.303"}]}]}]},{"type":"SECONDARY","title":"Mean Total Postoperative Opioid Consumption (in Morphine Equivalents) for HTX 011 Compared With Saline Placebo.","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.85","spread":"17.062"},{"groupId":"OG001","value":"17.53","spread":"18.908"}]}]}]},{"type":"SECONDARY","title":"Percetange of Subjects Who Are Opioid-free for HTX-011 Compared With Bupivacaine HCl.","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Total Postoperative Opioid Consumption (in Morphine Equivalents) for HTX 011 Compared With Bupivacaine HCl.","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.85","spread":"17.062"},{"groupId":"OG001","value":"14.51","spread":"18.185"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":163},"commonTop":["Nausea","Constipation","Dizziness","Headache","Dysgeusia"]}}}